Diagnostic and therapeutic aspects of receptor-mediated leukemog

Details Diagnostic and therapeutic aspects of receptor-mediated leukemog Diagnostic and therapeutic aspects of receptor-mediated leukemog

1985-01-15

1988-11-22

Marantz, Sidney

Chemistry: molecular biology and microbiology

Measuring or testing process involving enzymes or...

Involving virus or bacteriophage

424 86, 435 7, 435 29, 436519, 436548, 436813, G01N 33569, G01N 33574, G01N 33577, A61K 3900

Patent

active

047865903

ABSTRACT:
Specific binding members are provided for binding to lymphocytic cell surface receptors, which receptors are involved in the activation of a cell from the G.sub.0 state into the cell division cycle to proliferate. The cell surface receptors are further characterized by binding to envelope proteins of neoplasia-causing retroviruses, and/or to intact retroviral particles.

REFERENCES:
patent: 4391911 (1983-07-01), Tarro
patent: 4426446 (1984-01-01), Thompson
patent: 4513088 (1985-04-01), Levy
patent: 4545738 (1987-02-01), Knowles
patent: 4599305 (1986-07-01), Witte
Weissman, I. L., Life Sciences Research Report, 30, Leukemia, 235-249 (1985).
Cianciolo, G. J. et al., Science, 230 (4724), 453-455 (Oct. 25, 1985).
Cianciolo, G. J. et al., Nature, 311(5986), 515 (Oct. 1984).
Epstein, R. L. et al., Virology, 133(1), 46-55.

Affiliated with

Also associated with

Rating

Diagnostic and therapeutic aspects of receptor-mediated leukemog does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Diagnostic and therapeutic aspects of receptor-mediated leukemog, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Diagnostic and therapeutic aspects of receptor-mediated leukemog will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-435127